The CheckMate 143 trial was the first extensive evaluation of the efficacy of PD-1/PD-L1 immunotherapy for GBM, which assessed the efficacy of nivolumab (an anti-PD-1 monoclonal antibody) or bevacizumab in 369 patients with rGBM (64). The gene discussed is CD274; the disease is glioblastoma.